

### Targeting the Relaxin Autocrine Loop in High Grade Serous Ovarian Cancer using RLN2 Neutralizing Monoclonal Antibodies as a Therapeutic Strategy

July 1, 2017 to March 21, 2020

#### Highlights

- Developing a mAb targeting the Relaxin hormonal pathway as a therapeutic treatment for ovarian cancer
- Establish preclinical support for moving new therapeutic candidates into early-phase clinical testing.

## Ovarian Cancer

The goal of this project is to develop a panel of potent and selective RLN2 neutralizing antibodies that can be tested in high fidelity preclinical models of ovarian cancer.

Project value  
**\$424,500**  
BioCanRx contribution:  
**\$199,500**

Biotherapeutics  
**RLN2 neutralizing antibodies**

Partners  
**3**



Key investigator  
Lead:  
Dr. Robert **Rottapel**



#### About the project

Ovarian cancer has the highest mortality rate of all gynaecological cancers. The standard treatment for patients with ovarian cancer is surgery to reduce tumour burden followed by chemotherapy. Since ovarian cancer is generally not detectable at early stages, most women present with advanced stage disease. Although the majority of women initially respond to chemotherapy, more than 80% of patients will have a recurrence of their disease following treatment, and more than half will die of recurrent disease within 5 years of diagnosis. The identification of specific signaling pathways involved in ovarian tumorigenesis and tumour progression and development of novel treatment strategies to target these pathways is critical. There is an urgent unmet need to identify novel targets that can be drugged therapeutically.

The use of monoclonal antibodies (mAbs) or biologics that block signaling pathways supporting cancer growth has become a major treatment modality for cancer patients in recent years. Dr. Rottapel and his team of researchers propose to develop a mAb targeting the Relaxin hormonal pathway as a therapeutic treatment for ovarian cancer. Relaxin is a peptide hormone expressed in the ovary, which signals through the Relaxin Receptor (RXFP1). They have identified a dependency on Relaxin signaling for the survival and growth of ovarian cancer cells. Blockade of this pathway using a Relaxin targeting mAb or biologic therefore has the potential to antagonize the proliferation of ovarian cancer cells with high specificity.

Using functional genetic shRNA dropout screens the team has uncovered an autocrine loop required for ovarian cancer cell line and xenograft growth involving the mullerian hormone Relaxin and its G-protein coupled receptor RXFP1 (LGR7). They show that recombinant Relaxin stimulates mitogenic and survival signaling pathways and potently induces the expression of VEGF, metalloproteinases (MMPs), and COX2 each known to support epithelial tumourigenicity. Inflammatory cytokines IL-6 and TNF $\alpha$  frequently found in the tumour microenvironment induce Relaxin protein expression in ovarian cancer cell lines further amplifying the Relaxin autocrine loop. Therefore, inhibition of the Relaxin signaling pathway using neutralizing monoclonal antibodies has the potential to block the proliferation and metastatic spread of ovarian cancer cells through multiple mechanisms.

# Catalyst Program Investigators

**Toronto**  
Lunenfeld Research Centre,  
Mt. Sinai Hospital,  
Northern Biologics  
Princess Margaret Cancer Centre,  
University Health Network,  
University of Toronto  
Dr. Robert Rottapel  
Dr. Paul Boutros  
Dr. Johan Fransson  
Dr. Jeanne Magram  
Dr. Taymaa May  
Dr. Pam Ohashi  
Dr. Amit Oza  
Dr. Patricia Shaw

**Montreal**  
University of Montreal  
Dr. Anne-Marie Mes-Masson

**San Francisco, USA**  
Antibody Solutions  
Dr. Joshua Lowitz

**Tel-Aviv, Israel**  
Tel-Aviv University  
Dr. Itai Benhar

## Partners

Northern Biologics  
\$25,000

Ontario Institute for  
Cancer Research  
\$71,500

Princess Margaret  
Cancer Centre  
- University  
Health Network  
\$128,500

## Key Outputs

- Develop a panel of derived RLN2 neutralizing antibodies that will be tested in specific cell-based and biochemical assays.

- Test the efficacy of 10 lead mAbs to block proliferation of 4 ovarian cancer cell lines cultured as adherent cells, spheroids and in xenograft models.

The power to kill cancer lies within us.  
Let's tell our bodies how.